HUAPONT LIFE SCIENCES

HUAPONT LIFE SCIENCES was founded in 1992 and is a leading enterprise in the field of dermatological clinical drugs and skin health in China. It was listed on the Shenzhen Stock Exchange in 2004. After nearly 30 years of development, the company has formed a development pattern with the main direction of the large health industry, covering pharmaceuticals, healthcare, agrochemicals, new materials, tourism, and other fields. The company is currently China's leading clinical dermatological drug service provider, a leader in the pesticide industry, and an industry pioneer in fine chemical intermediates and new materials.The company’s headquarters is located in Chongqing Liangjiang New Area, a national-level development zone. It owns or holds shares in more than a hundred companies across more than ten provinces and cities in China such as Chongqing, Sichuan, Beijing, Zhejiang, as well as in overseas countries including the United States, Germany, and Switzerland. Globally, it employs over 12,000 people, and its products are sold in 58 countries and regions worldwide. Currently, the company controls three listed companies (Kaisheng New Materials, Yitai Biology, Lijiang Stock) and one company listed on the New Third Board (Qinling Tourism). As a national high-tech enterprise, the company adheres to the business philosophy of "Building a Healthy Great Wall for the Prosperity of China," emphasizing product research and technological innovation. Its drug treatment areas cover dermatology, tuberculosis, respiratory, anti-infection, oncology, ophthalmology, and more. The company currently owns two Class I new drugs, more than 20 first generics, and 18 drug specifications that have passed consistency evaluation. Several products are included in the National Key New Product Plan, and many production processes and technologies are leading both domestically and internationally.